Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery

K. Onizawa, K. Uchiyama, H. Iwabuchi, Kazuyuki Tsunoda, Y. Okada, S. Asanami

Research output: Contribution to journalArticle

Abstract

Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect. MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.

Original languageEnglish
Pages (from-to)10-14
Number of pages5
JournalOral Therapeutics and Pharmacology
Volume16
Issue number1
Publication statusPublished - 1997

Fingerprint

Oral Surgery
Methicillin-Resistant Staphylococcus aureus
Intravenous Infusions
Infection
habekacin
Therapeutics

Keywords

  • After oral and maxillofacial surgery
  • Arbekacin sulfate
  • MRSA infections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Onizawa, K., Uchiyama, K., Iwabuchi, H., Tsunoda, K., Okada, Y., & Asanami, S. (1997). Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery. Oral Therapeutics and Pharmacology, 16(1), 10-14.

Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery. / Onizawa, K.; Uchiyama, K.; Iwabuchi, H.; Tsunoda, Kazuyuki; Okada, Y.; Asanami, S.

In: Oral Therapeutics and Pharmacology, Vol. 16, No. 1, 1997, p. 10-14.

Research output: Contribution to journalArticle

Onizawa, K, Uchiyama, K, Iwabuchi, H, Tsunoda, K, Okada, Y & Asanami, S 1997, 'Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery', Oral Therapeutics and Pharmacology, vol. 16, no. 1, pp. 10-14.
Onizawa, K. ; Uchiyama, K. ; Iwabuchi, H. ; Tsunoda, Kazuyuki ; Okada, Y. ; Asanami, S. / Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery. In: Oral Therapeutics and Pharmacology. 1997 ; Vol. 16, No. 1. pp. 10-14.
@article{2a88dcb773184866acfe8a40de161fb4,
title = "Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery",
abstract = "Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8{\%}. As to the bacteriological effect. MRSA was eradicated in 4 (44.4{\%}) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0{\%} in 5 monotherapy cases and 83.3{\%} in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.",
keywords = "After oral and maxillofacial surgery, Arbekacin sulfate, MRSA infections",
author = "K. Onizawa and K. Uchiyama and H. Iwabuchi and Kazuyuki Tsunoda and Y. Okada and S. Asanami",
year = "1997",
language = "English",
volume = "16",
pages = "10--14",
journal = "Oral Therapeutics and Pharmacology",
issn = "0288-1012",
publisher = "Japanese Society of Oral Therapeutics and Pharmacology",
number = "1",

}

TY - JOUR

T1 - Clinical effects of arbekacin on MRSA infections after oral and maxillofacial surgery

AU - Onizawa, K.

AU - Uchiyama, K.

AU - Iwabuchi, H.

AU - Tsunoda, Kazuyuki

AU - Okada, Y.

AU - Asanami, S.

PY - 1997

Y1 - 1997

N2 - Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect. MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.

AB - Clinical and bacteriological effects of arbekacin (ABK) were studied in a total of 9 patients with methicillin-resistant Staphylococcus aureus (MRSA) infections after oral and maxillofacial surgery. ABK was administered by intravenous drip infusion at a close of 100mg twice a day for 7 to 14 days, and imipenem/cilastatin was administered to 3 patients, minocyclin to 1 patient, and lomefloxacin to 1 patient, simultaneously. The clinical efficacy rate of ABK was 77.8%. As to the bacteriological effect. MRSA was eradicated in 4 (44.4%) out of 9 patients. As to the administration methods, the clinical efficiencies were 80.0% in 5 monotherapy cases and 83.3% in 4 combined therapy cases. In conclusion, this study suggested that ABK is useful for treatment of MRSA infections after oral and maxillofacial surgery.

KW - After oral and maxillofacial surgery

KW - Arbekacin sulfate

KW - MRSA infections

UR - http://www.scopus.com/inward/record.url?scp=0030916997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030916997&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 10

EP - 14

JO - Oral Therapeutics and Pharmacology

JF - Oral Therapeutics and Pharmacology

SN - 0288-1012

IS - 1

ER -